Tag:

Actavis

Latest Headlines

Latest Headlines

Actavis execs up for $101M in merger-related bonuses, if investors approve

Through a storm of M&A activity, Actavis CEO Brent Saunders has climbed his way up into the CEO's chair at one of pharma's top 10 drugmakers--and it's a climb for which he's been well rewarded.

Actavis moves quickly to sell Australia generics business to Amneal

Actavis Australia has agreed to sell its generic pharmaceuticals business to Swiss-based Amneal Pharmaceuticals for an undisclosed amount, moving quickly to shed a unit that is not seen as core to the branded drug business after the merger with Allergan.

What's an Allergan career worth? $534M in cash, if you're ex-CEO David Pyott

Actavis' agreement to buy Allergan for $66 billion put then-Allergan CEO David Pyott in line for a hefty payout in cash and shares--and now that the tie-up is official, he's collecting.

Deals for Actavis, Teva plants put G&W in the spotlight; CEO says its culture is its beacon

G&W Laboratories, a small generic drugmaker, recently broke onto the pharma scene publicly with two substantial deals in 10 months for plants and products. The first deal was last summer when it bought an Actavis plant, and this month it announced a deal to do the same with Teva Pharmaceutical Industries.

Hedge fund patent challenges are growing by the numbers, and drugmakers aren't happy

Generics makers aren't the only ones filing challenges to pharma patents anymore. Hedge funds are doing it, too, and it's got drugmakers on edge.

Actavis job-cutting drive hits 400-plus on Long Island

New-look Actavis--soon to be Allergan--has been undergoing plenty of changes since it agreed in November to shell out $66 billion for the Botox maker. And as it continues to integrate Allergan's ops, it's shaving away at the workforce it inherited from its prior pickup, Forest Labs.

Old Allergan CEO Pyott won't join New Allergan's board

Allergan Chairman and CEO David Pyott fought long and hard to keep Valeant Pharmaceuticals from taking over his company. He engineered a $66 billion sale to ambitious Actavis instead, and the Allergan name now lives on as the merged company's moniker. But Pyott won't be sticking around to enjoy the results.

Actavis becomes Allergan and looks to manufacturing for cutting costs

Actavis has completed its $66 billion buyout of Allergan, which has implications for the manufacturing networks of the two companies.

All clear for Actavis to become Allergan as EU watchdogs approve $66B merger

Actavis and Allergan can finally celebrate: They've cleared the last hurdle to closing their $66 billion merger agreement.

FDA expands indication of the only sublingual second-gen antipsychotic

The FDA has expanded the indication of Actavis's Saphris tablet, the only sublingual atypical, or second-generation, antipsychotic to include pediatric patients aged 10 to 17 with bipolar I disorder.